Chen R et al. Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma. Proc ASH 2010;Abstract 283.

Dr Horwitz is Assistant Attending in the Division of Hematologic Oncology’s Lymphoma Service at Memorial Sloan-Kettering Cancer Center in New York, New York.